A novel immunotherapeutic approach to melanoma-bearing hosts with protein-transduction domain-containing immunogenic foreign antigens

Journal of Dermatological Science

Volumn 60, Issue 2, 2010, Pages 84-94

  Kanzaki, Mirei ^a   Okamoto, Takashi ^a   Mitsui, Hiroshi ^a   Shibagaki, Naotaka ^a   Shimada, Shinji ^a  

^a UNIVERSITY OF YAMANASHI   (Japan)

Author keywords

Cancer immunotherapy; Melanoma; Ovalbumin; Protein transduction

Indexed keywords

AUTOANTIGEN; PROTEIN TRANSDUCTION DOMAIN CONTAINING HUMAN FC RECEPTOR LIKE A AUTOANTIGEN; PROTEIN TRANSDUCTION DOMAIN CONTAINING IMMUNOGENIC FOREIGN ANTIGEN; PROTEIN TRANSDUCTION DOMAIN CONTAINING IRRELEVANT PROTEIN; PROTEIN TRANSDUCTION DOMAIN CONTAINING NATURAL TUMOR ASSOCIATED AUTOANTIGEN; PROTEIN TRANSDUCTION DOMAIN CONTAINING OVALBUMIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CANCER IMMUNOTHERAPY; CANCER INHIBITION; CANCER PREVENTION; CANCER REGRESSION; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; COMPARATIVE STUDY; CONTROLLED STUDY; FEMALE; IN VITRO STUDY; LYMPHOCYTE DEPLETION; LYMPHOCYTE SUBPOPULATION; MELANOMA; MELANOMA B16; MOUSE; NONHUMAN; PRIORITY JOURNAL;

ANALYSIS OF VARIANCE; ANIMALS; ANTIGENS; ANTIGENS, NEOPLASM; FEMALE; IMMUNOTHERAPY, ACTIVE; INJECTIONS, INTRALESIONAL; MELANOMA, EXPERIMENTAL; MICE; MICE, INBRED BALB C; MICE, INBRED C57BL; NEOPLASM PROTEINS; OLIGOPEPTIDES; OVALBUMIN; RECOMBINANT PROTEINS; T-LYMPHOCYTES, CYTOTOXIC;

EID: 77958486589     PISSN: 09231811     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.jdermsci.2010.08.009     Document Type: Article

References (35)

1. Kawakami Y., Eliyahu S., Delgado C.H., Robbins P.F., Sakaguchi K., Appella E., et al. Identification of a human melanoma antigen recognized by tumor-infiltrating lymphocytes associated with in vivo tumor rejection. Proc Natl Acad Sci USA 1994, 91:6458-6462.
2. Kawakami Y., Eliyahu S., Sakaguchi K., Robbins P.F., Rivoltini L., Yannelli J.R., et al. Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes. J Exp Med 1994, 180:347-352.
3. Dudley M.E., Wunderlich J.R., Robbins P.F., Yang J.C., Hwu P., Schwartzentruber D.J., et al. Cancer regression and autoimmunity in patients after clonal repopulation with antitumor lymphocytes. Science 2002, 298:850-854.
4. Rosenberg S.A., Yang J.C., Schwartzentruber D.J., Hwu P., Marincola F.M., Topalian S.L., et al. Immunologic and therapeutic evaluation of a synthetic peptide vaccine for the treatment of patients with metastatic melanoma. Nat Med 1998, 4:321-327.
5. Heath W.R., Kurts C., Miller J.F. Carbone FR cross-tolerance: a pathway for inducing tolerance to peripheral tissue antigens. J Exp Med 1998, 187:1549-1553.
6. Mitsui H., Inozume T., Kitamura R., Shibagaki N., Shimada S. Polyarginine-mediated protein delivery to dendritic cells presents antigen more efficiently onto MHC class I and class II and elicits superior antitumor immunity. J Invest Dermatol 2006, 126:1804-1812.
7. Inozume T., Matsuzaki Y., Kurihara S., Fujita T., Yamamoto A., Aburatani H., et al. Novel melanoma antigen, FCRL/FREB, identified by cDNA profile comparison using DNA chip are immunogenic in multiple melanoma patients. Int J Cancer 2005, 114:283-290.
8. Inozume T., Mitsui H., Okamoto T., Matsuzaki Y., Kawakami Y., Shibagaki N., Shimada S. Dendritic cells transduced with autoantigen FCRLA induce cytotoxic lymphocytes and vaccinate against murine B-cell lymphoma. J Invest Dermatol 2007, 127:2818-2822.
9. Mitsui H., Okamoto T., Kanzaki M., Inozume T., Shibagaki N., Shimada S. Intradermal injections of polyarginine-containing immunogenic antigens preferentially elicit Tc1 and Th1 activation and antitumour immunity. Br J Dermatol 2010, 162:29-41.
10. Shibagaki N., Udey M.C. Dendritic cells transduced with protein antigens induce cytotoxic lymphocytes and elicit antitumor immunity. J Immunol 2002, 168:2393-2401.
11. Shibagaki N., Udey M.C. Dendritic cells transduced with TAT protein transduction domain-containing tyrosinase-related protein 2 vaccinate against murine melanoma. Eur J Immunol 2003, 33:850-860.
12. Gurunathan S., Sacks D.L., Brown D.R., Reiner S.L., Charest H., Glaichenhaus N., Seder R.A. Vaccination with DNA encoding the immunodominant LACK parasite antigen confers protective immunity to mice infected with Leishmania major. J Exp Med 1997, 186:1137-1147.
13. Kronenberg K, Brosch S, Butsch F, Tada Y, Shibagaki N, Udey MC, et al. Vaccination with TAT-antigen fusion protein induces protective, CD8+ T cell-mediated immunity against Leishmania major. J Invest Dermatol; in press.
14. Suzue K., Zhou X., Eisen H.N., Young R.A. Heat shock fusion proteins as vehicles for antigen delivery into the major histocompatibility complex class I presentation pathway. Proc Natl Acad Sci USA 1997, 94:13146-13151.
15. + T cell subpopulations in established pulmonary metastases. J Immunol 1999, 162:6671-6680.
16. + effector T cell subpopulations promote long-term tumor immunity and protection to progressively growing tumor. J Immunol 2000, 164:916-925.
17. Dobrzanski M.J., Reome J.B., Dutton R.W. Immunopotentiating role of IFN-gamma in early and late stages of type 1 CD8 effector cell-mediated tumor rejection. Clin Immunol 2001, 98:70-84.
18. Helmich B.K., Dutton R.W. The role of adoptively transferred CD8 T cells and host cells in the control of the growth of the EG7 thymoma: factors that determine the relative effectiveness and homing properties of Tc1 and Tc2 effectors. J Immunol 2001, 166:6500-6508.
19. Yu H., Kortylewski M., Pardoll D. Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol 2007, 7:41-51.
20. Bhardwaj N. Harnessing the immune system to treat cancer. J Clin Invest 2007, 117:1130-1136.
21. Monney L., Sabatos C.A., Gaglia J.L., Ryu A., Waldner H., Chernova T., et al. Th1-specific cell surface protein Tim-3 regulates macrophage activation and severity of an autoimmune disease. Nature 2002, 415:536-541.
22. Toda M., Rabkin S.D., Kojima H., Martuza R.L. Herpes simplex virus as an in situ cancer vaccine for the induction of specific anti-tumor immunity. Hum Gene Ther 1999, 10:385-393.
23. Shen Y., Nemunaitis J. Herpes simplex virus 1 (HSV-1) for cancer treatment. Cancer Gene Ther 2006, 13:975-992.
24. Todo T. Oncolytic virus therapy using genetically engineered herpes simplex viruses. Front Biosci 2008, 13:2060-2064.
25. Prestwich R.J., Harrington K.J., Pandha H.S., Vile R.G., Melcher A.A., Errington F. Oncolytic viruses: a novel form of immunotherapy. Expert Rev Anticancer Ther 2008, 8:1581-1588.
26. Elliott G., O'Hare P. Intercellular trafficking and protein delivery by a herpesvirus structural protein. Cell 1997, 88:223-233.
27. Schwartz J.J., Zhang S. Peptide-mediated cellular delivery. Curr Opin Mol Ther 2000, 2:162-167.
28. Ford K.G., Souberbielle B.E., Darling D., Farzaneh F. Protein transduction: an alternative to genetic intervention?. Gene Ther 2001, 8:1-4.
29. Wybranietz W.A., Gross C.D., Phelan A., O'Hare P., Spiegel M., Graepler F., et al. Enhanced suicide gene effect by adenoviral transduction of a VP22-cytosine deaminase (CD) fusion gene. Gene Ther 2001, 8:1654-1664.
30. Armstrong C.A., Botella R., Galloway T.H., Murray N., Jill M., Kramp J.M., et al. Antitumor effects of granulocyte-macrophage colony-stimulating factor production by melanoma cells. Cancer Res 1996, 56:2191-2198.
31. Dissemond J., Weimann T.K., Schneide L.A., Schneeberger A., Scharffetter-Kochanek K., Goos M., et al. Activated neutrophils exert antitumor activity against human melanoma cells: reactive oxygen species-induced mechanisms and their modulation by granulocyte-macrophage - colony-stimulating factor. J Invest Dermatol 2003, 121:936-938.
32. + T cells. Immunol Rev 2006, 211:81-92.
33. Kortylewski M., Jover R., Yu H. Targeting STAT3 affects melanoma on multiple fronts. Cancer Metastasis Rev 2005, 24:315-327.
34. Kortylewski M., Yu H. Role of Stat3 in suppressing anti-tumor immunity. Curr Opin Immunol 2008, 20:228-233.
35. Skelton D., Satake N., Kohn D.B. The enhanced fluorescent protein is minimally immunogenic in C57BL/6 mice. Gene Ther 2001, 8:1813-1814.